AchieveRx (QUIT) Q3 2026 earnings review
AchieveRx completes U.S. drug batches, but launch costs climb
AchieveRx, a drug developer preparing to launch a smoking cessation pill, cleared a major manufacturing hurdle while its launch spending climbed. The company completed three commercial-scale stability batches at its new U.S. contract manufacturer, keeping its fourth-quarter FDA refiling on schedule. Chief executive Andrew D. Goldberg also reported 52-week trial results showing nearly one in three persistent smokers quit, while warrant exercises lifted cash to $202 million despite a $21 million operating loss.
| Loss from operations | $20.5M +40% from a year ago |
|---|---|
| Net loss, excluding warrant gain | $19.0M +32% from a year ago by our math |
| Cash and marketable securities | $201.5M $187.3M last quarter |
| FDA resubmission plan | Unchanged refile in Q4 2026; decision by end of Q2 2027 |
⚖️ Verdict: 🟢 Bullish
The story got better because completing the U.S. stability batches removes the main technical obstacle that caused the FDA to reject the drug in June. With warrant exercises also clearing the balance sheet's warrant liability into equity, the company has both the factory data to refile and the cash to prepare for a 2027 launch. One caution: operating expenses jumped 40% from a year ago, and the release newly mentions a dispute with raw-material supplier Sopharma AD while staying silent on when the Phase 3 vaping trial will start.
The question now is whether the new U.S. manufacturing data will satisfy the FDA without delay and allow the company to start its delayed vaping study. In the best case, the agency accepts the fourth-quarter filing and approves the drug by June 2027; in the worst case, inspection hurdles or the Sopharma dispute slow the rollout while higher overhead burns cash. The FDA's acceptance of the resubmission and the upcoming quarterly filing will tell.
🐂 Bull Case
U.S. Factory Completes Batches Needed to Refile
AchieveRx develops cytisinicline, an oral tablet that binds to nicotine receptors to help adults quit smoking or vaping. In June, the Food and Drug Administration (FDA) declined to approve the drug's New Drug Application (NDA), the formal request to sell a medicine in the United States, because a prior third-party factory failed an inspection.
To fix the issue, the drug developer moved production to U.S.-based Adare Pharma Solutions, "completing the production of three commercial-scale stability batches at Adare’s facility" this quarter. Those batches generate the shelf-life data required to refile in the fourth quarter, keeping a potential FDA decision on track for the end of the second quarter of 2027.
What to watch: formal confirmation of the NDA resubmission before year-end and whether the FDA classifies it as a two-month or six-month review. An accepted filing with a June 2027 target date would confirm that the Adare batch data satisfied the agency.
Year-Long Trial Shows Rising Quit Rates
Chief executive Andrew D. Goldberg said cytisinicline represents "what could be the first new FDA-approved prescription medicine in 20 years to help people who smoke quit." In October, the company presented 52-week results from ORCA-OL, a long-term open-label study of 479 adults who had failed to quit in earlier trials after a median of five prior attempts.
- Abstinence at Weeks 9 to 12: 25.5% of participants had quit for at least four weeks
- Abstinence at Weeks 49 to 52: 31.2% had quit by the end of the year
- Patients taking cytisinicline for the first time: 39.4% quit by the end of treatment
- Patients re-treated after failing on cytisinicline in an earlier trial: 27.8% quit
The independent safety committee found no new safety signals over the full year. Rising quit rates over 52 weeks give doctors a reason to prescribe longer courses or re-treat patients who relapse, which widens the commercial opportunity if the FDA approves the tablet.
What to watch: final product labeling discussions with the FDA during the upcoming review cycle. If the agency includes the 52-week ORCA-OL safety and re-treatment findings in the approved label, AchieveRx will have a stronger clinical case for insurers and doctors.
Warrant Exercises Lift Cash Above $200 Million
"The opportunity ahead of us is large, and so is our duty to fund it well," newly appointed finance chief Ben Halladay said. AchieveRx raised $180 million upfront in a second-quarter private placement that also included up to $174 million in warrants, which give investors the right to buy shares at a set price.
In the third quarter, cash and marketable securities rose by $14.2 million from last quarter to $201.5 million, driven by "proceeds received from the exercise of previously issued warrants." Meanwhile, the $183.4 million warrant liability on June's balance sheet moved into stockholders' equity, raising equity from negative $14.7 million to positive $180.7 million.
What to watch: remaining warrant exercises around the NDA resubmission and next year's FDA decision. The private placement includes milestone warrants exercisable up to 20 trading days after approval, which could bring in the rest of the $174 million to fund the commercial rollout.
🐻 Bear Case
Launch Hiring Drives Operating Loss Up 40%
AchieveRx reported a third-quarter net loss of $12.1 million, down from $14.4 million a year ago, while Halladay emphasized "disciplined capital allocation" ahead of next year's launch. However, the headline improvement came from a $6.9 million non-cash accounting gain on the fair value of warrant liabilities rather than lower spending.
- Net loss excluding the warrant gain: $19.0 million, up 31.6% from a year ago by our math
- Total operating expenses: $20.5 million, up 39.8% from a year ago and 11.7% from last quarter
- General and administrative expenses (overhead and launch team): $14.3 million, up 52.8% from a year ago
- Research and development expenses (clinical and manufacturing work): $6.2 million, up 16.8% from a year ago and 63.2% from last quarter
Hiring commercial executives and transferring manufacturing to Adare pushed quarterly operating burn above $20 million before a single sales rep takes the field. What to watch: quarterly operating expenses in the fourth quarter as the NDA is filed and sales hiring begins, because a climb toward $25 million per quarter would consume over half the cash pile before revenue starts.
Sopharma Escalates Into a Formal Dispute
Cytisinicline is made from a plant-based starting material historically supplied by Bulgarian drugmaker Sopharma AD. Earlier this year, management left Sopharma out of the initial FDA application over inspection readiness, while assuring investors it held more than three years of starting material in reserve and planned to add Sopharma after approval.
In this quarter's release, the risk disclosures newly warn that results could be hurt by "the outcome of the Company’s dispute with Sopharma AD." The release gives no details on what caused the conflict or whether raw material supply is affected, and it also omits any timeline for starting the Phase 3 ORCA-V2 vaping trial.
What to watch: the legal proceedings and supply chain notes in the upcoming third-quarter Form 10-Q filing. Any claim by Sopharma that restricts starting material deliveries or challenges intellectual property would threaten long-term commercial supply once the current stockpile runs down.
👓 Other Themes
Achieve Rebrands as AchieveRx and Hires CFO
On November 9, Achieve Life Sciences began doing business as AchieveRx, The Quit Company, and changed its Nasdaq ticker to QUIT. Alongside the rebrand, the company appointed Ben Halladay as finance chief and Kaitlyn Tuson as senior vice president of marketing and communications, following earlier hires to lead supply chain and quality.
💲 Other KPIs
Share count more than doubled from a year ago, rising 106.8% from 51.0 million in Q3 2025 and 12.8% from 93.5 million last quarter. The second-quarter private placement and third-quarter warrant exercises drove the increase, which spreads the company's net loss across twice as many shares.
Short-term unpaid bills and accrued expenses nearly doubled in three months, rising 89.1% from $5.4 million in June and up from $3.8 million at year-end 2025. The buildup reflects higher commercial preparation and Adare manufacturing activity that has been booked as an expense but not yet paid in cash.
Total debt fell 6.0% from $14.9 million in June, by our math, as non-current convertible debt declined from $7.5 million to $5.6 million while the current portion stayed at $7.5 million. With $201.5 million in cash and marketable securities, the pharmaceutical group holds $187.5 million in net cash.
🔮 Guidance
Unchanged. AchieveRx still plans to resubmit its smoking cessation application in the fourth quarter of 2026 and now specifies potential FDA approval by the end of the second quarter of 2027, with a U.S. commercial launch to follow. Specifying the end of Q2 2027 points to a standard six-month Class 2 FDA review following a late-2026 filing.
❓ Key Questions
What is the dispute with Sopharma AD about?
The forward-looking statements newly mention a dispute with starting-material supplier Sopharma AD. Investors need to know whether this involves supply obligations, payments, or intellectual property, and how much starting material AchieveRx currently holds.
When will the Phase 3 ORCA-V2 vaping trial begin?
Earlier in 2026, management hoped to start the pivotal ORCA-V2 vaping cessation trial this year after raising capital and securing an FDA priority voucher. The third-quarter release gives no update on trial initiation or clinical supply.
How much cash did warrant exercises bring in during Q3?
Cash rose by $14.2 million even though operating expenses reached $20.5 million. Because the release does not include a cash flow statement, investors cannot yet see exact gross warrant proceeds versus operating cash burn.
Has Adare passed an FDA inspection for solid oral tablets?
A third-party factory's failed inspection caused the June rejection. As Adare becomes the primary commercial manufacturer in the Q4 resubmission, its inspection history and readiness for a pre-approval inspection will decide whether the Q2 2027 target holds.